Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Ovarian Research
Published in: Journal of Ovarian Research 1/2018

Open Access 01-12-2018 | Review

DNA damage repair in ovarian cancer: unlocking the heterogeneity

Authors: Mary Ellen Gee, Zahra Faraahi, Aiste McCormick, Richard J. Edmondson

Published in: Journal of Ovarian Research | Issue 1/2018

Login to get access

Abstract

Treatment for advanced ovarian cancer is rarely curative; three quarters of patients with advanced disease relapse and ultimately die with resistant disease. Improving patient outcomes will require the introduction of new treatments and better patient selection. Abrogations in the DNA damage response (DDR) may allow such stratifications.
A defective DNA-damage response (DDR) is a defining hallmark of high grade serous ovarian cancer (HGSOC). Indeed, current evidence indicates that all HGSOCs harbour a defect in at least one major DDR pathway. However, defective DDR is not mediated through a single mechanism but rather results from a variety of (epi)genetic lesions affecting one or more of the five major DNA repair pathways. Understanding the relationship between these pathways and how these are abrogated will be necessary in order to facilitate appropriate selection of both existing and novel agents.
Here we review the current understanding of the DDR with regard to ovarian, and particularly high grade serous, cancer, with reference to existing and emerging treatments as appropriate.
Literature
1.
Mukhopadhyay A, et al. Clinicopathological features of homologous recombination deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum and survival. Cancer Res. 2012;72(22):5675–82.CrossRefPubMed
2.
Ledermann J, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852–61.CrossRefPubMed
3.
Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005;5(9):689–98.CrossRefPubMed
4.
Kennedy R, AD D’A. DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes. J Clin Oncol. 2006;24(23):3799–808.CrossRefPubMed
5.
Zhong Q, Chen CF, Li S, et al. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science. 1999;285:747–50.CrossRefPubMed
6.
Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001;27:247–54.CrossRefPubMed
7.
TCGA. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.CrossRef
8.
King MC, Marks JH, Mandell JB. Breast and ovarian Cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643–6.CrossRefPubMed
9.
Hilton J, Geisler JP, Rathe J, Hattermann-Zogg M, DeYoung B, Buller R, Inactivation of BRCA1 and BRCA2 in ovarian Cancer. J Natl Cancer Inst. 2002;94(18):1396–406.
10.
Catteau A, Harris WH, Xu CF, Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene. 1999;18(11):1957–65.CrossRefPubMed
11.
Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Nardod S, Karlan BY. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 2000;60(19):5329–33.PubMed
12.
Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med. 2010;12(5):245–59.CrossRefPubMed
13.
Risch HA, McLaughlin JR, Cole D, Rosen B, et al. Prevalence and penetrance of Germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian Cancer. Am J Human Genet. 2001;68(3):700–10.CrossRef
14.
Boyd J, Sonoda Y, Federici MG. Clinicopathologic features of BRCA-linked and sporadic Ovarioan Cancer. JAMA. 2000;283:2260–5.CrossRefPubMed
15.
Cass I, Baldwin RL, Varkey T. Improved Survival in Women with BRCA-Associated Ovarian Carcinoma. Cancer. 2003;97(9):2187–95.CrossRefPubMed
16.
Choudhury A, Zhao H, Jalali F, Al Rashid S, Ran J, Supiot S, Kiltie AE, Bristow RG. Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol Can Ther. 2009;8(1):203–13.CrossRef
17.
Bryant HE, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–7.CrossRefPubMed
18.
Farmer H, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21.CrossRefPubMed
19.
Fong PC, Yap TA, Boss DS, et al. Poly(ADP) - Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Ovarian Cancer Correlating with Platinum-Free Interval. J Clin Oncol. 2010;28(15):2512–9.CrossRefPubMed
20.
Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer. N Engl J Med. 2012;366:1382–92.CrossRefPubMed
21.
Mirza MR, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154–64.CrossRefPubMed
22.
Wang H, Wang H, Powell SN, Iliakis G, Wang Y. ATR affecting cell radiosensitivity is dependent on homologous recombination repair but independent of nonhomologous end joining. Cancer Res. 2004;64(19):7139–43.CrossRefPubMed
23.
Peasland A, Wang LZ, Rowling E, Kyle S, Chen T, et al. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell line. Br J Cancer. 2011;105:372–81.CrossRefPubMedPubMedCentral
24.
25.
Lieber MR, Ma Y, Pannicke U, Schwarz K. Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol. 2003;4:712–20.CrossRefPubMed
26.
Beucher A, Birraux J, Tchouandong L, Barton O, et al. ATM and Artemis promote homologous recombination of radiation-induced DNA double-strand breaks in G2. EMBO J. 2009;28:3413–27.CrossRefPubMedPubMedCentral
27.
Burma S, Chen BP, Chen DJ. Role of non-homologous end joining (NHEJ) in maintaining genomic integrity. DNA Repair. 2006;5(9–10):1042–8.CrossRefPubMed
28.
Valerie K, Povirk LF. Regulation and mechanisms of mammalian double-strand break repair. Oncogene. 2003;22:5792–812.CrossRefPubMed
29.
McCormick A, S.N., Curtin NJ, Edmondson RJ, (n.d.) Non Homologous End Joining pathways defects in human cancers.
30.
31.
West RB, Yaneva M, Lieber MR. Productive and Nonproductive complexes of Ku and DNA-dependent protein kinase at DNA termini. Mol Cell Biol. 1998;18:5908–20.CrossRefPubMedPubMedCentral
32.
Ma Y, Pannicke U, Schwarz K, Leiber MR. Hairpin Opening and Overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell. 2002;108:781–94.CrossRefPubMed
33.
34.
Ahnesorg P, Smith P, Jackson SP. XLF Interacts with the XRCC4-DNA Ligase IV Complex to Promote DNA Nonhomologous End-Joining. Cell. 2005;124(2):287–99.
35.
Dueva R, Iliakis G. Alternative pathways of non-homologous end joining (NHEJ) in genomic instability and cancer. Transl Cancer Res. 2013;2(3):163–77.
36.
Kent T, Chandramouly G, McDevitt SM, et al. Mechanism of microhomology-mediated end-joining promoted by human DNA polymerase Θ. Nat Struct Mol Biol. 2015;22(3):230–9.CrossRefPubMedPubMedCentral
37.
Wang M, Wu W, Wu W, Rosidi B, Zhang L, Wang H, Iliakis G. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res. 2006;34(21):6170–82.CrossRefPubMedPubMedCentral
38.
Audebert M, Salles B, Calsou P. Involvement of poly(ADP-ribose) polymerase 1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem. 2004;279(53):55117–26.CrossRefPubMed
39.
Mansour WY, Rhein T, Dahm-Daphi J. The alternative end-joining pathway for repair of DNA double-strand breaks requires PARP1 but is not dependent upon microhomologies. Nucleic Acids Res. 2010;38(18):6065–77.CrossRefPubMedPubMedCentral
40.
McCormick, A., et al., Ovarian Cancers Harbour Defects in Non-Homologous End Joining Resulting in Resistance to Rucaparib. Clin Canc res, 2016. Published OnlineFirst October 4, 2016.
41.
Abdel-Fatah T, Arora A, Moseley P, Coveney C, Perry C, Johnson K, Kent C, Ball G, Chan S, Madhusudan S. AMT, ART and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers. BBA Clinical. 2014;2:10–7.CrossRefPubMedPubMedCentral
42.
Couto CA, Wang HY, Green JC, et al. PARP regulates nonhomologous end joining through retention of Ku at double strand breaks. J Cell Biol. 2011;194(3):367–75.CrossRefPubMedPubMedCentral
43.
Hochegger H, Dejsuphong D, et al. PARP 1 protects homolgous recombination from interference by Ku and Ligase IV in vertebrate cells. EMBO J. 2006;25(6):1305–14.CrossRefPubMedPubMedCentral
44.
Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly (ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A. 2011;108(8):3406–11.CrossRefPubMedPubMedCentral
45.
Schildkraut JM, Iversen ES, Wilson MA, Clyde MA, et al. Association between DNA damage response and repair genes and risk of invasive serous ovarian Cancer. PLoS One. 2010;5(4):e10061.CrossRefPubMedPubMedCentral
46.
Pearce CL, Near AM, Van Den Berg DJ, et al. Validating genetic risk associations for ovarian cancer through the international ovarian Cancer association consortium. Br J Cancer. 2009;100:412–20.CrossRefPubMedPubMedCentral
47.
Ceccaldi R, Liu JC, Amunugama R et al, Homologous recombination deficient tumours are dependent on PolΘ mediated repair. Nature. 2015;518:258–62.
48.
Miao J, Zhang X, Tang QL, Wang XY, Kai L. Prediction value of XRCC1 gene polymorphisms on the survival of ovarian cancer treated by adjuvant chemotherapy. Asian Pac J Cancer Prev. 2012;13:5007–10.CrossRefPubMed
49.
Adel-Fatah T, Sultana R, Abbotts R, Hawkes C, Seedhouse C, Chan S, Madhasudan S. Clinicopathological and functional significance of XRCC1 expression in ovarian cancer. Int J Cancer. 2012;132:2778–86.CrossRef
50.
Cooke SL, Ng CK, Melnyk N, Garcia MJ, Hardcastle T, Temple J, Langdon S, Huntsman D, Brenton JD. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene. 2010;29(35):4905–13.CrossRefPubMedPubMedCentral
51.
Stronach EA, Chen M, Maginn EN, Agarwal R, Mills GB, Wasan H, Gabra H. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia. 2011;13(11):1069–80.CrossRefPubMedPubMedCentral
52.
Ohtaa T, Ohmichi M, et al. Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells. Cancer Biol Ther. 2012;13(6):408–16.CrossRef
53.
Diggle CP, Bentley J, et al. Inhibition of double strand break non-homologous end-joining by cisplatin adducts in human cell extracts. Nucleic Acids Res. 2005;33(8):2531–9.CrossRefPubMedPubMedCentral
54.
55.
Leahy JJ, Golding BT, Griffin RJ, et al. Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU 7441) by screening of chromosome libraries. Bioorg Med Chem Lett. 2004;14:6083–7.CrossRefPubMed
56.
Zhao Y, Thomas HD, Batey MA, et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res. 2006;66:5354–62.CrossRefPubMed
57.
Sultana R, Abdel-Fatah T, Abbotts R, Hawkes C, Albarakati N, Seedhouse C, Ball G, Chan S, Rakha EA, Ellis IO, Madhusudan S. Targeting XRCC1 Deficiency in Breats Cancer for Personalised Therapy. Cancer Res. 2012;73(5):1621–34.CrossRefPubMed
58.
59.
Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer. 2012;12:801–17.CrossRefPubMed
60.
Osorio A, Milne RL, et al. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet. 2014;10(4):e1004256.CrossRefPubMedPubMedCentral
61.
Pieretti M, Khattar NH, Smith SA. Common polymorphisms and somatic mutations in human base excision repair genes in ovarian and endometrial cancers. Mut Res Gen. 2001;432:53–9.
62.
Albertella MR, Lau A, O’Connor MJ. The overexpression of specialized DNA polymerases in cancer. DNA Repair. 2005;4(5):583–93.CrossRefPubMed
63.
Al-Attar A, Gossage L, Fareed KR, et al. Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers. Br J Cancer. 2010;102:704–9.CrossRefPubMedPubMedCentral
64.
Huehls AM, Wagner JM, Huntoon CJ, Karnitz LM. Identification of DNA repair pathways that affect the survival of ovarian Cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination. Mol Pharmacol. 2012;82:767–76.CrossRefPubMedPubMedCentral
65.
66.
MJ OC. Targeting the DNA damage response in Cancer. Mol Cell. 2015;60:547–60.CrossRef
67.
Boudsocq F, Benaim P, et al. Modulation of Cellular Response to Cisplatin by a Novel Inhibitor of DNA Polymerase. Mol Pharmacol. 2005;67(5):1485–97.CrossRefPubMed
68.
Gao Z, Maloney DJ, Dedkova LM, Hecht SM. Inhibitors of DNA polymerase β: activity and mechanism. Bioorg Med Chem. 2008;16:4331–40.CrossRefPubMed
69.
Kumamoto-Yonezawa Y, et al. Enhancement of human cancer cell radiosensitivity by conjugated eicosapentaenoic acid - a mammalian DNA polymerase inhibitor. Int J Oncol. 2010;36:577–84.PubMed
70.
Zhang Y, Wang J, Xiang D, Wang D, Xin X. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor. Int J Oncol. 2009;35:1069–79.CrossRefPubMed
71.
Taverna P, Liu L, Hwang HS, et al. Methoxyamine potentiates DNA single strand breaks and double strand breaks induces by temozolomide in colon cancer cells. Mutat Res. 2001;485(4):269–81.CrossRefPubMed
72.
Fishel ML, He Y, Smith ML, Kelley MR. Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Clin Cancer Res. 2007;13(1):260–7.CrossRefPubMed
73.
G-M L. Mechanisms and functions of DNA mismatch repair. Cell Res. 2008;18:85–98.CrossRef
74.
Watson P, Bützow R, Lynch HT, et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynaecol Oncol. 2001;82:223–8.CrossRef
75.
Jensen KC, Mariappan MR, Putcha GV, Husain A, Chun N, Ford JM, et al. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplams in patients 50 years of age and younger. Am J Surg Pathol. 2008;32(7):1029–37.CrossRefPubMed
76.
Song H, Cicek MS, Dicks E, et al. The contibution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet. 2014;23(17):4703–9.CrossRefPubMedPubMedCentral
77.
P, K. Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis. 2001;22(12):1931–7.CrossRef
78.
Martin LP, Hamilton TC, Schilder RJ. Platinum Resistance: The Role of DNA Repair Pathways. Clin Cancer Res. 2008;14(5):1291–5.CrossRefPubMed
79.
Helleman J, van Staveren IL et al. Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer. 2006;6(201):201.
80.
81.
Branch P, Masson M, Aquilina G, et al. Spontaneous development of drug resistance: mismatch repair defects in resistance to cisplatin in human tumor cells. Oncogene. 2000;19:3138–45.CrossRefPubMed
82.
Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000;60:6039–44.PubMed
83.
Herrero AB, Martín-Castellanos C, Marco E, et al. Cross-Talk between Nucleotide Excision and Homologous Recombination DNA Repair Pathways in the Mechanism of Action of Antitumor Trabectedin. Cancer Res. 2006;66(16):8155–62.CrossRefPubMed
84.
Patch AM, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489–94.CrossRefPubMed
85.
Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson S, Drew Y, Kyle S, Los G, Hostomsky Z, Edmondson R, Curtin N. Development of a Functional Assay for Homolgous Recombination Status in Primary Culture of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors. Clinical Cancer Research. 2010;16(8):2344–51.CrossRefPubMed
86.
Woodhouse L, Mcormick A, O’Donnell R, Kauffmann A, Edmondson R. Development of a functional assay to determine the nucleotide excision repair status of epithelial ovarian cancer. Liverpool: NCRI Cancer Conference; 2014.
87.
Ceccaldi R, et al. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res. 2015;75(4):628–34.CrossRefPubMedPubMedCentral
88.
Wang Q-E, Milum K, Han C, Huang Y-W et al Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells Mol Cancer. 2011;10(24):24.
89.
Buterin T, Hess MT, Gunz D, et al. Trapping of DNA Nucleotide Excision Repair Factors by Nonrepairable Carcinogen Adducts. Cancer Res. 2002;62(15):4229–35.PubMed
90.
O'Sullivan R, D P, Curtin N, Kaufmann A, McCormick A, Edmondson RJ. DNA-PK as a biomarker of non-homologous end joining in ovarian cancer. Liverpool: NCRI Cancer Conference; 2014.
91.
Tomkinson AE, Vijayakumar S, Pascal JM, Ellenberger T. DNA ligases: structure, reaction mechanism, and function. Chem Rev. 2006;106:687–99.CrossRefPubMed
92.
Heikkinen K, Karppinen SM, Soini Y, Makinen M, Wingvist R, Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility. J Med Genet. 2003;40(12):e131.
93.
94.
Caiola E, Porcu L, Fruscio R, et al. DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer. Pharmacogenomics J. 2013;13:159–72.CrossRefPubMed
95.
96.
Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in Cisplatin-resistant ovarian Cancer cells. Biochem Pharmacol. 2000;60:1305–13.CrossRefPubMed
97.
Stevens EV, Raffeld M, Espina V, et al. Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. Cancer. 2005;103(11):2313–9.CrossRefPubMed
98.
Dabholkar M, Thornton K, Vionnet J, Bostick-Bruton F, et al. Increased mRNA levels of Xeroderma Pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or Methallothionein-II (MT-II) in platinum resistant human ovarina cancer tissues. Biochem Pharmacol. 2000;60:1611–9.CrossRefPubMed
Metadata
Title
DNA damage repair in ovarian cancer: unlocking the heterogeneity
Authors
Mary Ellen Gee
Zahra Faraahi
Aiste McCormick
Richard J. Edmondson
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2018
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/s13048-018-0424-x

Other articles of this Issue 1/2018

Journal of Ovarian Research 1/2018 Go to the issue

Research

Intrafollicular fibroblast growth factor 13 in polycystic ovary syndrome: relationship with androgen levels and oocyte developmental competence

Research

Comparison of stage III mucinous and serous ovarian cancer: a case-control study

Research

Consanguineous familial study revealed biallelic FIGLA mutation associated with premature ovarian insufficiency

Case report

Persistent megalocystic ovaries after ovarian hyperstimulation syndrome in a postpartum patient with polycystic ovarian syndrome: a case report

Research

Adipokine RBP4 drives ovarian cancer cell migration

Research

MR findings of primary ovarian granulosa cell tumor with focus on the differentiation with other ovarian sex cord-stromal tumors